• A 83-01: ALK-5 Inhibitor Workflow Guide

  2026-08-15

  A 83-01 enables controlled TGF-β pathway inhibition across reporter assays, EMT models, organoids, and stem-cell differentiation workflows. This guide connects dose planning and formulation with the reference study’s practical comparison of trophoblast protocols, while highlighting controls and troubleshooting steps for reproducible results.

• EV-Transferred ACLY Drives TAM Formation in HCC

  2026-08-14

  The Advanced Science study identifies extracellular vesicle transfer of ATP-citrate lyase as a direct metabolic signal that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its CD81-targeted liposomal models establish a causal link between ACLY-driven palmitate production, immune-checkpoint protein stability, tumor progression, and improved anti-PD-1/PD-L1 responses.

• Vorinostat Workflow for Cancer Biology Research

  2026-08-14

  Build a reproducible Vorinostat workflow that connects HDAC target engagement with chromatin remodeling, cell-cycle arrest, and intrinsic apoptosis. The guide also shows how to benchmark responses across lymphoma and neuroblastoma models while avoiding common solvent, timing, and assay-normalization errors.

• Azithromycin and Roxithromycin as Senolytics

  2026-08-13

  Ozsvari et al. used DNA-damage-induced human fibroblast senescence to identify azithromycin and roxithromycin as selective senolytic candidates, while the closely related erythromycin lacked comparable activity. The study combines protein-content, real-time impedance, and metabolic analyses, providing a useful framework for drug repurposing and orthogonal senescent cell detection.

• Dual-Mode mRNA Reporters for Translational Decisions

  2026-08-13

  Translational mRNA research increasingly depends on separating delivery, intracellular fate, and functional protein expression. This thought-leadership article examines how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), combined with disciplined formulation and imaging workflows, can turn those variables into actionable development data.

• miR-24-3p, Sp1/PI3K, and Doxorubicin Heart Failure

  2026-08-12

  The reference study identifies miR-24-3p as a direct regulator of Sp1 in doxorubicin-induced heart failure, linking microRNA activity to PI3K-associated cardiomyocyte protection. Its combined rat, cell, inhibitor, gene-manipulation, and dual-luciferase design provides a useful mechanistic framework, while the model limitations caution against immediate clinical or cross-disease translation.

• EPI-001: AR N-Terminal Domain Inhibitor Workflow

  2026-08-12

  EPI-001 enables pathway-level interrogation of full-length and splice-variant androgen receptor signaling in prostate cancer and selected AR-positive TNBC models. This practical guide links N-terminal inhibition to cell-growth, transcriptional, migration, and EMT assays while addressing solubility, vehicle, and interpretation risks.

• Go 6983 and WDR36: PKC–Glycolysis Tests

  2026-08-11

  Go 6983 provides a pharmacological way to test whether PKC activity contributes to WDR36-dependent glycolysis and trophectoderm differentiation. This article translates a recent human blastoid study into a stage-aware assay framework while separating demonstrated biology from hypotheses requiring validation.

• Captopril Beyond Blood Pressure: A Translational ACE Map

  2026-08-11

  Captopril is more than a conventional ACE inhibitor: it is a mechanistically tractable probe for connecting renin–angiotensin signaling, vascular physiology, intestinal reflexes, and apoptosis-oriented oncology research. This thought-leadership guide shows how to use the compound strategically while separating established evidence from testable cross-domain hypotheses.

• N-MYC–eIF4G1 Axis in inv(16) AML

  2026-08-10

  The 2024 Science Advances study identifies an N-MYC–eIF4G1 survival program in inv(16) acute myeloid leukemia. By combining transcriptomic reanalysis, regulatory-element investigation, human leukemia models, and patient-derived xenografts, the authors connect MYCN deregulation to leukemic maintenance and define eIF4G1 as a previously unrecognized effector.

• (-)-JQ1 for Rigorous BET Control Workflows

  2026-08-09

  Use (-)-JQ1, the inactive JQ1 stereoisomer, to distinguish BET-dependent biology from vehicle, stress, and off-target effects. This practical guide connects stereochemical controls with BRD4 target gene modulation, oxidative-stress assays, and reproducible epigenetics research workflows.

• AG-221 (Enasidenib): From 2-HG to AML Dependency

  2026-08-08

  AG-221 (Enasidenib) is more than an IDH2 inhibitor: it enables a layered analysis of 2-hydroxyglutarate reduction, differentiation, and metabolic dependency. This article translates recent CD44 findings into a rigorous assay framework for acute myeloid leukemia research.

• AZ505: Selective SMYD2 Inhibitor for Reliable Assays

  2026-08-07

  Learn how AZ505, a potent and selective SMYD2 inhibitor, can improve the design and interpretation of viability, proliferation, and cytotoxicity assays. This scenario-based guide covers mechanism, compound handling, protocol optimization, renal fibrosis evidence, and practical selection of SKU B1255.

• CHIR-99021 (CT99021): Enabling Precision in Directed Stem Ce

  2026-08-07

  Explore the pivotal role of CHIR-99021 in directed stem cell differentiation, focusing on its unique mechanism and protocol innovations. Discover how this selective GSK-3 inhibitor advances both assay reliability and translational applications.

• Valemetostat (DS-3201): Advanced Epigenetic Modulation in EZ

  2026-08-06

  Explore how Valemetostat drives next-generation epigenetic cancer therapy, with a focus on its dual EZH1/EZH2 inhibition and unique clinical applications in relapsed or refractory follicular lymphoma. This in-depth review offers distinct mechanistic insights and practical assay guidance beyond standard protocol summaries.

11629 records 1/776 page Next 12345 下5页 Last page